RxDoctor Payments Data

David Burks, MD

Urology · Jackson, MINPI 1033279906

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,663 of the $21,509 with a category attached, or 91.4%. Astellas Pharma US Inc accounts for 97.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $21,183 and has fallen 99.2% since, to $163 in 2024. Among urology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,509in general payments, 2019–2025

Across 35 payments — averaging $614.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$21K
  • Coloplast$139
  • Boston Scientific$113
  • Medtronic$111
  • Ambu Inc.$67
  • Tolmar Pharmaceuticals, Inc.$24
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$19,66391%
  • Travel & lodging$8894%
  • Food & beverage$9574%

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,509 in reported general payments places this provider in the 90th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$114,578
Medicare patients
486
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron106$75,602
Solifenacin Succinate253$11,016
Tamsulosin Hcl225$4,431
Oxybutynin Chloride ErOxybutynin Chloride64$1,549
Finasteride56$1,258
Tolterodine Tartrate ErTolterodine Tartrate27$1,034
Trospium Chloride17$1,033
Bicalutamide21$683
Ciprofloxacin Hcl126$471
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$362
Alfuzosin Hcl ErAlfuzosin Hcl14$323
Imipramine Hcl26$278
Cephalexin55$206
Tramadol Hcl93$119
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$21,009$75,602106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 urology providers in Michigan.

Other urology in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →